Clinitouch-360: A digital health platform enabling robust end-to-end care of patients in Primary Care with depression and anxiety

Clinitouch-360：数字健康平台，可为初级保健中的抑郁和焦虑患者提供强大的端到端护理

• 批准号: 10098274
• 金额: $ 34.88万
• 依托单位: SPIRIT DIGITAL LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10098274
• 关键词: Clinitouch; 360; digital; health; platform

Public descriptionIn the UK \\\>10 million people aged 18+ (16.7% of the adult population) have depression (costing £70 billion/year from 91 million days of lost work, plus health and social care costs) and \\\>8 million have an anxiety disorder.Despite the prevalence of these conditions and shared treatment modalities (talking therapy, medication, self-support) patients presenting with anxiety and depression can experience significant problems with their care:* Incorrect diagnosis due to insufficient initial assessment (the prevalence of unrecognised bipolar disorder is 10% amongst patients prescribed antidepressants in primary care for depression or anxiety).* Deteriorating mental health during delays waiting for treatment initiation (talking therapy waitlists are 3-5 months; a 2022 Royal College of Psychiatrists report stated 43% of patients experience decline whilst waiting to start treatment).* Only 40% of patients receive medication reviews within time frames recommended in NICE guidelines, resulting in patients taking ineffective medications, or experiencing serious side effects.* Studies indicate that 30--60% of long-term antidepressant prescriptions are inappropriate.* 56% of people reducing antidepressants experience withdrawal symptoms. 46% of these patients describe their symptoms as severe and lasting for weeks or months. Gradual and hyperbolic tapering to medication cessation can mitigate this, but patients do not receive specialist support for this.* Clinicians frequently experience difficultly differentiating withdrawal symptoms from disease re-emergence when withdrawing antidepressants or anxiolytics.There is an unmet need for a digital tool supporting precision medicine and improved end-to-end management of these patients in primary care to achieve better outcomes.Solution: Spirit Digital has commercialised the 'Clinitouch' remote patient monitoring platform. Spirit will create a new module (Clinitouch-360) to better manage patients with anxiety and depression from their initial presentation.Clinitouch-360 will automate time-consuming elements of NICE guidance that prevent best practice being followed and deploy technological innovations that support patients across their treatment pathway.

公开描述在英国，1000 万 18 岁以上的人（占成年人口的 16.7%）患有抑郁症（每年损失 9100 万天工作，加上医疗和社会护理费用，造成 700 亿英镑的损失），并且“超过 800 万人患有焦虑症。尽管这些病症普遍存在并且采用共同的治疗方式（谈话疗法、药物治疗、自我支持），但患有焦虑和抑郁的患者仍可能在护理中遇到重大问题：* 由于诊断不足而导致错误诊断初步评估（在初级保健中因抑郁或焦虑而开出抗抑郁药的患者中，未被识别的双相情感障碍的患病率为 10%）。* 在等待治疗开始的延误期间心理健康状况恶化（谈话治疗候补名单为 3-5 个月；2022 年皇家学院精神科医生报告指出，43% 的患者在等待开始治疗时会出现病情下降。* 只有 40% 的患者在 NICE 指南建议的时间范围内接受药物审查，导致患者服用药物无效或出现严重副作用。*研究表明，30--60% 的长期抗抑郁药处方是不合适的。*减少抗抑郁药用量的人中有 56% 出现戒断症状，​​其中 46% 的患者描述其症状严重且持久。持续数周或数月逐渐和双曲线逐渐减量直至停药可以缓解这种情况，但患者得不到专家的支持。*临床医生经常难以区分戒断症状和疾病复发。停用抗抑郁药或抗焦虑药。对于支持精准医疗和改善初级保健中这些患者的端到端管理以实现更好结果的数字工具的需求尚未得到满足。解决方案：Spirit Digital 已将“Clinitouch”远程患者监护平台商业化Spirit 将创建一个新模块 (Clinitouch-360)，以更好地管理患有焦虑症和抑郁症的患者，从最初的表现开始。Clinitouch-360 将自动执行 NICE 指南中耗时的元素，这些元素会阻碍最佳实践的实施。跟踪并部署技术创新，为患者的整个治疗路径提供支持。